Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bulevirtide · Hepcludex

Peptide · Antagonist of NTCP (SLC10A1) · developed by Gilead Sciences

Approved FDA, May 2026

GILD Developer

1 Registered trials

What is Bulevirtide?

Bulevirtide is a synthetic 47-amino acid lipopeptide derived from the HBV preS1 domain. It inhibits HDV infection by binding to the NTCP receptor on hepatocytes, blocking HDV attachment.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Hepcludex
Drug type: Peptide
Targets: NTCP (SLC10A1)
Mechanism: Antagonist of NTCP (SLC10A1)
Therapy area: Infectious disease
Developer: Gilead Sciences Inc (GILD)
FDA status: Approved as Hepcludex (May 22, 2026), BLA761468 · FDA label
UNII: WKM56H3TLB

✅ FDA-approved uses

Chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis

From the indications section of the FDA label (version of May 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05718700	N/A	Chronic Hepatitis D Infection	Terminated	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis D Infection

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Bulevirtide

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z